{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T01:50:33Z","timestamp":1780710633196,"version":"3.54.1"},"reference-count":98,"publisher":"e-Century Publishing Corporation","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Dis"],"DOI":"10.62347\/rpmz6407","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T21:51:22Z","timestamp":1736286682000},"page":"396-413","source":"Crossref","is-referenced-by-count":9,"title":["Long-acting nifedipine in the management of essential hypertension: a review for cardiologists"],"prefix":"10.62347","volume":"14","author":[{"given":"Prakash Kumar","family":"Hazra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S0140-6736(07)61299-9","article-title":"Essential hypertension","volume":"370","author":"FH","year":"2007","unstructured":"Messerli FH, Williams B and Ritz E. Essential hypertension. Lancet 2007; 370: 591-603.","journal-title":"Lancet"},{"key":"ref1","unstructured":"Hypertension. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hypertension."},{"key":"ref2","unstructured":"Fatima S and Mahmood S. Combatting a silent killer - the importance of self-screening of blood pressure from an early age. EXCLI J 2021; 20: 1326-1327."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/S0140-6736(21)01688-3","article-title":"Global and national high blood pressure burden and control","volume":"398","author":"Nguyen","year":"2021","unstructured":"Nguyen TN and Chow CK. Global and national high blood pressure burden and control. Lancet 2021; 398: 932-933.","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Prenissl J, Manne-Goehler J, Jaacks LM, Prabhakaran D, Awasthi A, Bischops AC, Atun R, Bärnighausen T, Davies JI, Vollmer S and Geldsetzer P. Hypertension screening, awareness, treatment, and control in India: a nationally representative cross-sectional study among individuals aged 15 to 49 years. PLoS Med 2019; 16: e1002801.","DOI":"10.1371\/journal.pmed.1002801"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ihj.2019.09.012","article-title":"Prevalence of hypertension among Indian adults: results from the great India blood pressure survey","volume":"71","author":"Ramakrishnan","year":"2019","unstructured":"Ramakrishnan S, Zachariah G, Gupta K, Shivkumar Rao J, Mohanan PP, Venugopal K, Sateesh S, Sethi R, Jain D, Bardolei N, Mani K, Kakar TS, Kidambi B, Bhushan S, Verma SK, Bhargava B, Roy A, Kothari SS, Gupta R, Bansal S, Sood S, Nath RK, Tyagi S, Gupta MD, Girish MP, Kalra IPS, Wander GS, Gupta S, Mandal S, Senguttuvan NB, Subramanyam G, Roy D, Datta S, Ganguly K, Routray SN, Mishra SS, Singh BP, Bharti BB, Das MK, Kumar S, Goswami KC, Bahl VK, Chandra S, Banerjee A, Guha S, Deb PK, Chopra HK, Deedwania P and Seth A; CSI-Great India BP Campaign Investigators. Prevalence of hypertension among Indian adults: results from the great India blood pressure survey. Indian Heart J 2019; 71: 309-313.","journal-title":"Indian Heart J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1097\/HJH.0000000000000146","article-title":"Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension","volume":"32","author":"Anchala","year":"2014","unstructured":"Anchala R, Kannuri NK, Pant H, Khan H, Franco OH, Di Angelantonio E and Prabhakaran D. Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension. J Hypertens 2014; 32: 1170-1177.","journal-title":"J Hypertens"},{"key":"ref7","unstructured":"Ministry of Health and Family Welfare. National Action Plan and Monitoring Framework for Prevention and Control of Non-Communicable Diseases (NCDs) in India (2017-2022). https:\/\/mainmohfwgovin\/sites\/default\/files\/National%20Multisectoral%20Action%20Plan%20%28NMAP%29%20for%20Prevention%20and%20Control%20of%20Common%20NCDs%20%282017-22%29_1pdf."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41371-020-0349-x","article-title":"Indian guidelines on hypertension-IV (2019)","volume":"34","author":"Shah","year":"2020","unstructured":"Shah SN, Munjal YP, Kamath SA, Wander GS, Mehta N, Mukherjee S, Kirpalani A, Gupta P, Shah H, Rohatgi R, Billimoria AR, Maiya M, Das MK, Goswami KC, Sharma R, Rajapurkar MM, Chawla R, Saboo B and Jha V. Indian guidelines on hypertension-IV (2019). J Hum Hypertens 2020; 34: 745-758.","journal-title":"J Hum Hypertens"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.2147\/VHRM.S3661","article-title":"Long-acting nifedipine in the management of the hypertensive patient","volume":"4","author":"ME","year":"2008","unstructured":"Snider ME, Nuzum DS and Veverka A. Long-acting nifedipine in the management of the hypertensive patient. Vasc Health Risk Manag 2008; 4: 1249-1257.","journal-title":"Vasc Health Risk Manag"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/eurheartj\/ehl001","article-title":"Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the management of stable angina pectoris of the European Society of Cardiology","volume":"27","author":"Fox","year":"2006","unstructured":"Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, Daly C, De Backer G, Hjemdahl P, Lopez-Sendon J, Marco J, Morais J, Pepper J, Sechtem U, Simoons M, Thygesen K, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Andreotti F, Becher H, Dietz R, Fraser A, Gray H, Antolin RAH, Huber K, Kremastinos DT, Maseri A, Nesser HJ, Pasierski T, Sigwart U, Tubaro M and Weis M. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the management of stable angina pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341-1381.","journal-title":"Eur Heart J"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Evbayekha EO, Okobi OE, Okobi T, Ibeson EC, Nwafor JN, Ozobokeme OE, Olawoye A, Ngoladi IA, Boms MG, Habib FA, Oyelade BO, Okoroafor CC, Chukwuma VN, Alex KB and Ohikhuai EE. The evolution of hypertension guidelines over the last 20+ years: a comprehensive review. Cureus 2022; 14: e31437.","DOI":"10.7759\/cureus.31437"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD and Wright JT Jr. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Hypertension 2018; 71: e13-e115.","DOI":"10.1161\/HYP.0000000000000065"},{"key":"ref13","unstructured":"Hamrahian SM. Pathophysiology of hypertension: pathogenesis of essential hypertension, factors influencing bp regulation, etiology of essential hypertension. https:\/\/emedicine.medscape.com\/article\/1937383-overview."},{"key":"ref14","unstructured":"Brettler J. BMJ Best Practice Essential hypertension. https:\/\/bestpractice.bmj.com\/topics\/en-gb\/26."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s13410-022-01143-7","article-title":"RSSDI Guidelines for the management of hypertension in patients with diabetes mellitus","volume":"42","author":"Kumar","year":"2022","unstructured":"Kumar V, Agarwal S, Saboo B and Makkar B. RSSDI Guidelines for the management of hypertension in patients with diabetes mellitus. Int J Diabetes Dev Ctries 2022; 42: 576-605.","journal-title":"Int J Diabetes Dev Ctries"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.jacc.2008.08.036","article-title":"Resistant hypertension: an overview of evaluation and treatment","volume":"52","author":"Sarafidis","year":"2008","unstructured":"Sarafidis PA and Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008; 52: 1749-1757.","journal-title":"J Am Coll Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0828-282X(09)70496-9","article-title":"Resistant hypertension","volume":"25","author":"Tobe","year":"2009","unstructured":"Tobe SW and Lewanczuk R. Resistant hypertension. Can J Cardiol 2009; 25: 315-317.","journal-title":"Can J Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, Lackland DT, Laffer CL, Newton-Cheh C, Smith SM, Taler SJ, Textor SC, Turan TN and White WB; American Heart Association Professional\/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension 2018; 72: e53-e90.","DOI":"10.1161\/HYP.0000000000000084"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1161\/CIRCRESAHA.118.312156","article-title":"Treatment of resistant and refractory hypertension","volume":"124","author":"Acelajado","year":"2019","unstructured":"Acelajado MC, Hughes ZH, Oparil S and Calhoun DA. Treatment of resistant and refractory hypertension. Circ Res 2019; 124: 1061-1070.","journal-title":"Circ Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.22270\/jddt.v12i4-S.5483","article-title":"Nicardia® XL (nifedipine extended release): technologically advanced GITS formulation ensures robust efficacy and assured safety","volume":"12","author":"Mavani","year":"2022","unstructured":"Mavani S, Abraham M, Conjeevaram A, Singh S, Revandkar V and Birla A. Nicardia® XL (nifedipine extended release): technologically advanced GITS formulation ensures robust efficacy and assured safety. Journal of Drug Delivery and Therapeutics 2022; 12: 181-191.","journal-title":"Journal of Drug Delivery and Therapeutics"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/j.1552-4604.1991.tb01905.x","article-title":"The effect of nifedipine GITS on renal function in hypertensive patients with renal insufficiency","volume":"31","author":"Reams","year":"1991","unstructured":"Reams G, Lau A, Knaus V and Bauer JH. The effect of nifedipine GITS on renal function in hypertensive patients with renal insufficiency. J Clin Pharmacol 1991; 31: 468-472.","journal-title":"J Clin Pharmacol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/IBPC.S34803","article-title":"A review of the gastrointestinal therapeutic system (GITS) formulation and its effectiveness in the delivery of antihypertensive drug treatment (focus on nifedipine GITS)","volume":"6","author":"Meredith","year":"2013","unstructured":"Meredith PA and Elliott HL. A review of the gastrointestinal therapeutic system (GITS) formulation and its effectiveness in the delivery of antihypertensive drug treatment (focus on nifedipine GITS). Integr Blood Press Control 2013; 6: 79-87.","journal-title":"Integr Blood Press Control"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"482","DOI":"10.2165\/00019053-199405060-00005","article-title":"Translating safety, efficacy and compliance into economic value for controlled release dosage forms","volume":"5","author":"Cramer","year":"1994","unstructured":"Cramer MP and Saks SR. Translating safety, efficacy and compliance into economic value for controlled release dosage forms. Pharmacoeconomics 1994; 5: 482-504.","journal-title":"Pharmacoeconomics"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Vetrovec GW. Once-daily therapy for angina pectoris with nifedipine gastrointestinal therapeutic system. Dosing and clinical efficacy. Am J Med 1989; 86: 28-32.","DOI":"10.1016\/0002-9343(89)90007-7"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1080\/08038020310000113","article-title":"Case report of three cases","volume":"1","author":"Kawano","year":"2003","unstructured":"Kawano H, Ashizawa N, Toda G, Seto S and Yano K. Administration of nifedipine CR immediately after awakening prevents a morning surge in hypertensive patients. Case report of three cases. Blood Press Suppl 2003; 1: 44-48.","journal-title":"Blood Press Suppl"},{"key":"ref26","unstructured":"Khan KM, Patel JB and Schaefer TJ. Nifedipine. In: StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Jayesh Patel declares no relevant financial relationships with ineligible companies. Disclosure: Timothy Schaefer declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright © 2024, StatPearls Publishing LLC.; 2024."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/j.1875-9114.1996.tb03011.x","article-title":"Comparison of two formulations of nifedipine during 24-hour ambulatory blood pressure monitoring","volume":"16","author":"Granberry","year":"1996","unstructured":"Granberry MC, Gardner SF, Schneider EF and Carter IR. Comparison of two formulations of nifedipine during 24-hour ambulatory blood pressure monitoring. Pharmacotherapy 1996; 16: 932-936.","journal-title":"Pharmacotherapy"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Carr AA, Bottini PB, Feig P, Prisant LM, Mulligan S, Devane JG, Fisher L, Rhoades RB and MacCarthy EP. Effectiveness of once-daily monotherapy with a new nifedipine sustained release calcium antagonist. Am J Cardiol 1992; 69: 28E-32E.","DOI":"10.1016\/0002-9149(92)90015-Q"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0149-2918(97)80046-X","article-title":"Nifedipine gastrointestinal therapeutic system (GITS) for hypertensive patients in a primary care setting: results of the Extended Release Adalat Canadian Trial (EXACT)","volume":"19","author":"Toal","year":"1997","unstructured":"Toal CB, Mahon WA, Barnes C and Burelle D. Nifedipine gastrointestinal therapeutic system (GITS) for hypertensive patients in a primary care setting: results of the Extended Release Adalat Canadian Trial (EXACT). Clin Ther 1997; 19: 924-935.","journal-title":"Clin Ther"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/0002-9343(87)90634-6","article-title":"A multicenter study of 54 patients","volume":"83","author":"Bittar","year":"1987","unstructured":"Bittar N, Corder CN, Eich R, McGrew FA 3rd, Paulk EA and Zellner S. Efficacy of nifedipine gastrointestinal therapeutic system in combination with beta blockers in the management of exertional angina. A multicenter study of 54 patients. Am J Med 1987; 83: 30-33.","journal-title":"Am J Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1517\/17425255.3.5.769","article-title":"Nifedipine gastrointestinal therapeutic system: an overview of its antiatherosclerotic effects","volume":"3","author":"Ueng","year":"2007","unstructured":"Ueng KC, Lin MC, Chan KC and Lin CS. Nifedipine gastrointestinal therapeutic system: an overview of its antiatherosclerotic effects. Expert Opin Drug Metab Toxicol 2007; 3: 769-780.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/ajh\/2.3.188","article-title":"Short-term and long-term renal response to nifedipine monotherapy","volume":"2","author":"GP","year":"1989","unstructured":"Reams GP, Lau A and Bauer JH. Short-term and long-term renal response to nifedipine monotherapy. Am J Hypertens 1989; 2: 188-190.","journal-title":"Am J Hypertens"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.2147\/DDDT.S117221","article-title":"Early intervention of long-acting nifedipine GITS reduces brachial-ankle pulse wave velocity and improves arterial stiffness in Chinese patients with mild hypertension: a 24-week, single-arm, open-label, prospective study","volume":"10","author":"Zhang","year":"2016","unstructured":"Zhang J, Wang Y, Hu H, Yang X, Tian Z, Liu D, Gu G, Zheng H, Xie R and Cui W. Early intervention of long-acting nifedipine GITS reduces brachial-ankle pulse wave velocity and improves arterial stiffness in Chinese patients with mild hypertension: a 24-week, single-arm, open-label, prospective study. Drug Des Devel Ther 2016; 10: 3399-3406.","journal-title":"Drug Des Devel Ther"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1161\/01.CIR.0000046488.52939.BF","article-title":"Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function)","volume":"107","author":"Investigators","year":"2003","unstructured":"ENCORE Investigators. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation 2003; 107: 422-428.","journal-title":"Circulation"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1161\/hc3601.095927","article-title":"Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial","volume":"104","author":"RB","year":"2001","unstructured":"Devereux RB, Palmieri V, Sharpe N, De Quattro V, Bella JN, de Simone G, Walker JF, Hahn RT and Dahlöf B. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation 2001; 104: 1248-1254.","journal-title":"Circulation"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Textor SC, Schwartz L, Wilson DJ, Wiesner R, Romero JC, Augustine J, Kos P, Hay E, Gores G and Dickson ER. Systemic and renal effects of nifedipine in cyclosporine-associated hypertension. Hypertension 1994; 23 Suppl: I220-4.","DOI":"10.1161\/01.HYP.23.1_Suppl.I220"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3109\/10641963.2011.583968","article-title":"Comparison of daily anti-hypertensive effects of amlodipine and nifedipine coat-core using ambulatory blood pressure monitoring - utility of “hypobaric curve” and “hypobaric area”","volume":"33","author":"Kuga","year":"2011","unstructured":"Kuga K, Xu DZ, Ohtsuka M, Aonuma K, Lau AH, Watanabe Y and Ohtsuka K. Comparison of daily anti-hypertensive effects of amlodipine and nifedipine coat-core using ambulatory blood pressure monitoring - utility of “hypobaric curve” and “hypobaric area”. Clin Exp Hypertens 2011; 33: 231-239.","journal-title":"Clin Exp Hypertens"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/hr.2009.18","article-title":"Influence of nifedipine coat-core and amlodipine on systemic arterial stiffness modulated by sympathetic and parasympathetic activity in hypertensive patients","volume":"32","author":"Fukuda","year":"2009","unstructured":"Fukuda M, Masuda T, Ogura MN, Moriya T, Tanaka K, Yamamoto K, Ishii A, Yonezawa R, Noda C and Izumi T. Influence of nifedipine coat-core and amlodipine on systemic arterial stiffness modulated by sympathetic and parasympathetic activity in hypertensive patients. Hypertens Res 2009; 32: 392-398.","journal-title":"Hypertens Res"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Richardson PJ, Meany TB, Johnston GD, Kondowe G, Grimmer SF and Breckenridge AM. Comparative efficacy of lisinopril and nifedipine retard in essential hypertension: a double-blind, placebo-controlled trial. J Cardiovasc Pharmacol 1987; 10 Suppl 10: S96-98.","DOI":"10.1097\/00005344-198710100-00035"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1097\/HJH.0b013e3282ef7adc","article-title":"Crossover study of amlodipine versus nifedipine CR with home blood pressure monitoring via cellular phone: internet-mediated open-label crossover trial of calcium channel blockers for hypertension (i-TECHO trial)","volume":"25","author":"Ryuzaki","year":"2007","unstructured":"Ryuzaki M, Nakamoto H, Nishida E, Sone M, Nakajima S, Yoshimoto M, Suzuki Y and Itagaki K. Crossover study of amlodipine versus nifedipine CR with home blood pressure monitoring via cellular phone: internet-mediated open-label crossover trial of calcium channel blockers for hypertension (i-TECHO trial). J Hypertens 2007; 25: 2352-2358.","journal-title":"J Hypertens"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/08037050510034257","article-title":"Effects of nifedipine GITS 20 mg or enalapril 20 mg on blood pressure and inflammatory markers in patients with mild-moderate hypertension","volume":"1","author":"Rosei E","year":"2005","unstructured":"Agabiti Rosei E, Morelli P and Rizzoni D. Effects of nifedipine GITS 20 mg or enalapril 20 mg on blood pressure and inflammatory markers in patients with mild-moderate hypertension. Blood Press Suppl 2005; 1: 14-22.","journal-title":"Blood Press Suppl"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S0149-2918(96)80022-1","article-title":"Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension","volume":"18","author":"Weir","year":"1996","unstructured":"Weir MR, Elkins M, Liss C, Vrecenak AJ, Barr E and Edelman JM. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Clin Ther 1996; 18: 411-428.","journal-title":"Clin Ther"},{"key":"ref43","unstructured":"Chamiec T, Zaleska T, Kłoś J, Pietrzykowska H, Bednarz B and Ceremuzyński L. Efficacy and tolerance of nifedipine retard vs acebutolol in patients with essential hypertension treated for 26 weeks. Mater Med Pol 1989; 21: 49-52."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/0002-9343(87)90631-0","article-title":"A preliminary experience","volume":"83","author":"Frishman","year":"1987","unstructured":"Frishman WH, Garofalo JL, Rothschild A, Rothschild M, Greenberg SM and Soberman J. Multicenter comparison of the nifedipine gastrointestinal therapeutic system and long-acting propranolol in patients with mild to moderate systemic hypertension receiving diuretics. A preliminary experience. Am J Med 1987; 83: 15-19.","journal-title":"Am J Med"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/00045391-199807000-00006","article-title":"Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial","volume":"5","author":"Nueten L","year":"1998","unstructured":"Van Nueten L, Lacourcière Y, Vyssoulis G, Korlipara K, Marcadet DM, Dupont AG and Robertson JI. Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial. Am J Ther 1998; 5: 237-243.","journal-title":"Am J Ther"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1136\/pgmj.60.706.529","article-title":"Comparison of nifedipine (retard formulation) and mefruside in the treatment of mild to moderate hypertension--a prospective randomized double-blind crossover study in general practice","volume":"60","author":"Douglas-Jones","year":"1984","unstructured":"Douglas-Jones AP and Mitchell AD. Comparison of nifedipine (retard formulation) and mefruside in the treatment of mild to moderate hypertension--a prospective randomized double-blind crossover study in general practice. Postgrad Med J 1984; 60: 529-532.","journal-title":"Postgrad Med J"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1161\/01.HYP.33.1.24","article-title":"Safety of nifedipine in angina pectoris: a meta-analysis","volume":"33","author":"Stason","year":"1999","unstructured":"Stason WB, Schmid CH, Niedzwiecki D, Whiting GW, Caubet JF, Cory D, Luo D, Ross SD and Chalmers TC. Safety of nifedipine in angina pectoris: a meta-analysis. Hypertension 1999; 33: 24-31.","journal-title":"Hypertension"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1161\/01.HYP.28.1.109","article-title":"Comparison of nifedipine alone and with diltiazem or verapamil in hypertension","volume":"28","author":"Saseen","year":"1996","unstructured":"Saseen JJ, Carter BL, Brown TE, Elliott WJ and Black HR. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. Hypertension 1996; 28: 109-114.","journal-title":"Hypertension"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2215\/CJN.14610920","article-title":"Resistant hypertension in CKD","volume":"16","author":"Thomas","year":"2021","unstructured":"Thomas G and Rahman M. Resistant hypertension in CKD. Clin J Am Soc Nephrol 2021; 16: 467-469.","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref50","unstructured":"Dong B, Guan S, Ge B, Yan S, Qin S, Zhang B, Pin L, Li F and Wu X. Therapeutic effect and prognostic life quality of renal denervation therapy and nifedipine combined with metoprolol tartrate in the treatment of resistant hypertension. Int J Clin Exp Med 2019; 12: 13723-13731."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1007\/s12325-021-01850-3","article-title":"Effectiveness and tolerability of nifedipine GITS in patients with chronic kidney disease and uncontrolled hypertension: a prospective, multicenter, observational study (ADRENAL)","volume":"38","author":"Lv","year":"2021","unstructured":"Lv R, Chen J, Wang H, Wang J, Cheng H, Li R, Li W, Zhang T, Wei L, Chen Q, Huang J, Yu F, Shen S, Wu H, Liu C, Hong F, Liu J, Zhang X, Xiao H and Song W. Effectiveness and tolerability of nifedipine GITS in patients with chronic kidney disease and uncontrolled hypertension: a prospective, multicenter, observational study (ADRENAL). Adv Ther 2021; 38: 4771-4785.","journal-title":"Adv Ther"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.clinthera.2016.02.025","article-title":"Safety of the up-titration of nifedipine GITS and valsartan or low-dose combination in uncontrolled hypertension: the FOCUS study","volume":"38","author":"JB","year":"2016","unstructured":"Park JB, Shin JH, Kim DS, Youn HJ, Park SW, Shim WJ, Park CG, Kim DW, Lee HY, Choi DJ, Rim SJ, Lee SY and Kim JH; FOCUS Investigators. Safety of the up-titration of nifedipine GITS and valsartan or low-dose combination in uncontrolled hypertension: the FOCUS study. Clin Ther 2016; 38: 832-842.","journal-title":"Clin Ther"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0011-393X(05)80775-1","article-title":"Effect of combination therapy with arotinolol and sustained-release nifedipine in patients with essential hypertension resistant to monotherapy","volume":"55","author":"Takeda","year":"1994","unstructured":"Takeda K, Nakata T, Uchida A, Fujita H, Nakamura K, Takesako T, Itoh H, Sasaki S and Nakagawa M. Effect of combination therapy with arotinolol and sustained-release nifedipine in patients with essential hypertension resistant to monotherapy. Curr Ther Res 1994; 55: 817-827.","journal-title":"Curr Ther Res"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/oxfordjournals.eurheartj.a014668","article-title":"The TIBET Study Group","volume":"17","author":"Dargie","year":"1996","unstructured":"Dargie HJ, Ford I and Fox KM. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Eur Heart J 1996; 17: 104-112.","journal-title":"Eur Heart J"},{"key":"ref55","unstructured":"Liu XR, Wang CA, Tang CS, Li SH, Xiao K, Peng L and Chen CX. Influence of nifedipine controlled release tablets combined with indapamide on renal function of elderly patients with refractory isolated systolic hypertension. Journal of Clinical Medicine in Practice 2014; 79-80, 93."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"432","DOI":"10.4021\/jocmr1563w","article-title":"Efficacies of controlling morning blood pressure and protecting the kidneys by treatment with valsartan and nifedipine CR or valsartan and amlodipine (MONICA Study)","volume":"5","author":"Tanaka","year":"2013","unstructured":"Tanaka T, Miura S, Tanaka M, Uehara Y, Hirano T and Saku K. Efficacies of controlling morning blood pressure and protecting the kidneys by treatment with valsartan and nifedipine CR or valsartan and amlodipine (MONICA Study). J Clin Med Res 2013; 5: 432-440.","journal-title":"J Clin Med Res"},{"key":"ref57","unstructured":"Heagerty AM, Bing RF, Thurston H and Swales JD. Nifedipine substituted for minoxidil in the treatment of refractory hypertension. J Hum Hypertens 1987; 1: 83-86."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V and Desormais I; ESC Scientific Document Group. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39: 3021-3104.","journal-title":"Eur Heart J"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 203: chronic hypertension in pregnancy. Obstet Gynecol 2019; 133: e26-e50.","DOI":"10.1097\/AOG.0000000000003020"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4103\/npmj.npmj_275_20","article-title":"Efficacy of nifedipine versus hydralazine in the management of severe hypertension in pregnancy: a randomised controlled trial","volume":"27","author":"Adebayo","year":"2020","unstructured":"Adebayo JA, Nwafor JI, Lawani LO, Esike CO, Olaleye AA and Adiele NA. Efficacy of nifedipine versus hydralazine in the management of severe hypertension in pregnancy: a randomised controlled trial. Niger Postgrad Med J 2020; 27: 317-324.","journal-title":"Niger Postgrad Med J"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Sahai R, Nidhi A, Ranjan R and Lal S. Comparative study of oral nifedipine versus intravenous labetalol in severe hypertension in pregnancy: a randomized controlled study. Int J Obstet Gynecol Res 2020; 7: 75-80.","DOI":"10.18231\/j.ijogr.2020.016"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1213\/ANE.0000000000002304","article-title":"National partnership for maternal safety: consensus bundle on severe hypertension during pregnancy and the postpartum period","volume":"125","author":"Bernstein","year":"2017","unstructured":"Bernstein PS, Martin JN Jr, Barton JR, Shields LE, Druzin ML, Scavone BM, Frost J, Morton CH, Ruhl C, Slager J, Tsigas EZ, Jaffer S and Menard MK. National partnership for maternal safety: consensus bundle on severe hypertension during pregnancy and the postpartum period. Anesth Analg 2017; 125: 540-547.","journal-title":"Anesth Analg"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1111\/bcp.13649","article-title":"Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials","volume":"84","author":"Sridharan","year":"2018","unstructured":"Sridharan K and Sequeira RP. Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. Br J Clin Pharmacol 2018; 84: 1906-1916.","journal-title":"Br J Clin Pharmacol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/S0002-9378(99)70315-7","article-title":"A randomized, double-blind, hemodynamic evaluation of nifedipine and labetalol in preeclamptic hypertensive emergencies","volume":"181","author":"Scardo","year":"1999","unstructured":"Scardo JA, Vermillion ST, Newman RB, Chauhan SP and Hogg BB. A randomized, double-blind, hemodynamic evaluation of nifedipine and labetalol in preeclamptic hypertensive emergencies. Am J Obstet Gynecol 1999; 181: 862-866.","journal-title":"Am J Obstet Gynecol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.18203\/2320-1770.ijrcog20191943","article-title":"Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomized controlled trial","volume":"8","author":"Alam","year":"2019","unstructured":"Alam A and Zakaria S. Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomized controlled trial. Int J Reprod Contracept Obstet Gynecol 2019; 8: 1921-1928.","journal-title":"Int J Reprod Contracept Obstet Gynecol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report","volume":"289","author":"AV","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr and Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.","journal-title":"JAMA"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1067\/mob.2002.126294","article-title":"Efficacy and safety of nifedipine tablets for the acute treatment of severe hypertension in pregnancy","volume":"187","author":"Brown","year":"2002","unstructured":"Brown MA, Buddle ML, Farrell T and Davis GK. Efficacy and safety of nifedipine tablets for the acute treatment of severe hypertension in pregnancy. Am J Obstet Gynecol 2002; 187: 1046-1050.","journal-title":"Am J Obstet Gynecol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/j.1471-0528.2000.tb13342.x","article-title":"Nifedipine administered in pregnancy: effect on the development of children at 18 months","volume":"107","author":"Bortolus","year":"2000","unstructured":"Bortolus R, Ricci E, Chatenoud L and Parazzini F. Nifedipine administered in pregnancy: effect on the development of children at 18 months. BJOG 2000; 107: 792-794.","journal-title":"BJOG"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2147\/IJWH.S159062","article-title":"Effectiveness of nifedipine in threatened preterm labor: a randomized trial","volume":"10","author":"Songthamwat","year":"2018","unstructured":"Songthamwat S, Na Nan C and Songthamwat M. Effectiveness of nifedipine in threatened preterm labor: a randomized trial. Int J Womens Health 2018; 10: 317-323.","journal-title":"Int J Womens Health"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/j.1471-0528.2006.00851.x","article-title":"Long-term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour","volume":"113","author":"Houtzager","year":"2006","unstructured":"Houtzager BA, Hogendoorn SM, Papatsonis DN, Samsom JF, van Geijn HP, Bleker OP and van Wassenaer AG. Long-term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG 2006; 113: 324-331.","journal-title":"BJOG"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(19)31282-6","article-title":"Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial","volume":"394","author":"Easterling","year":"2019","unstructured":"Easterling T, Mundle S, Bracken H, Parvekar S, Mool S, Magee LA, von Dadelszen P, Shochet T and Winikoff B. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. Lancet 2019; 394: 1011-1021.","journal-title":"Lancet"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1161\/HYPERTENSIONAHA.122.19751","article-title":"Trial of intrapartum extended-release nifedipine to prevent severe hypertension among pregnant individuals with preeclampsia with severe features","volume":"80","author":"Cleary","year":"2023","unstructured":"Cleary EM, Racchi NW, Patton KG, Kudrimoti M, Costantine MM and Rood KM. Trial of intrapartum extended-release nifedipine to prevent severe hypertension among pregnant individuals with preeclampsia with severe features. Hypertension 2023; 80: 335-342.","journal-title":"Hypertension"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3390\/pharmaceutics15020556","article-title":"Virtual clinical trials guided design of an age-appropriate formulation and dosing strategy of nifedipine for paediatric use","volume":"15","author":"Khan","year":"2023","unstructured":"Khan D, Badhan R, Kirby DJ, Bryson S, Shah M and Mohammed AR. Virtual clinical trials guided design of an age-appropriate formulation and dosing strategy of nifedipine for paediatric use. Pharmaceutics 2023; 15: 556.","journal-title":"Pharmaceutics"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"189","DOI":"10.25100\/cm.v37i3.444","article-title":"Nifedipine and captopril in hypertensive crisis in children","volume":"37","author":"Zapata","year":"2006","unstructured":"Zapata F, Fernandez C, de Rovetto C, de Castaño I, Roa JA and Echandía CA. Nifedipine and captopril in hypertensive crisis in children. Colombia Médica 2006; 37: 189-195.","journal-title":"Colombia M&#xE9 dica"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/s00467-004-1444-x","article-title":"The safety and use of short-acting nifedipine in hospitalized hypertensive children","volume":"19","author":"Yiu","year":"2004","unstructured":"Yiu V, Orrbine E, Rosychuk RJ, MacLaine P, Goodyer P, Girardin C, Gowrishankar M, Ogborn M, Midgley J, Filler G and Harley F. The safety and use of short-acting nifedipine in hospitalized hypertensive children. Pediatr Nephrol 2004; 19: 644-650.","journal-title":"Pediatr Nephrol"},{"key":"ref76","unstructured":"Nourse PJ and McCulloch MI. Evaluation of the safety of shortacting nifedipine use in children with severe hypertension secondary to acute post-streptococcal glomerulonephritis. S Afr J Child Health 2007; 1: 34-37."},{"key":"ref77","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1067\/mpd.2001.114699","article-title":"The use of short-acting nifedipine in pediatric patients with hypertension","volume":"139","author":"RT","year":"2001","unstructured":"Blaszak RT, Savage JA and Ellis EN. The use of short-acting nifedipine in pediatric patients with hypertension. J Pediatr 2001; 139: 34-37.","journal-title":"J Pediatr"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S1773-2247(05)50056-X","article-title":"The need for pædiatric formulation: oral administration of nifedipine in children, a proof of concept","volume":"15","author":"Tuleu","year":"2005","unstructured":"Tuleu C, Grangé J and Seurin S. The need for pædiatric formulation: oral administration of nifedipine in children, a proof of concept. J Drug Deliv Sci Technol 2005; 15: 319-324.","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1212\/WNL.0b013e318230201a","article-title":"Short-acting nifedipine and risk of stroke in elderly hypertensive patients","volume":"77","author":"Jung","year":"2011","unstructured":"Jung SY, Choi NK, Kim JY, Chang Y, Song HJ, Lee J and Park BJ. Short-acting nifedipine and risk of stroke in elderly hypertensive patients. Neurology 2011; 77: 1229-1234.","journal-title":"Neurology"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Schubert I, Hein R, Abbas S and Thürmann P. The frequency of prescription of immediate-release nifedipine for elderly patients in Germany: utilization analysis of a substance on the PRISCUS list of potentially inappropriate medications. Dtsch Arztebl Int 2012; 109: 215-219.","DOI":"10.3238\/arztebl.2012.0215"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s002280050344","article-title":"Twenty-four-hour blood pressure monitoring during treatment with extended-release felodipine versus slow-release nifedipine in elderly patients with mild to moderate hypertension: a randomized, double-blind, cross-over study","volume":"53","author":"Bonaduce","year":"1997","unstructured":"Bonaduce D, Canonico V, Petretta M, Forgione L, Ianniciello A, Cavallaro V, Bertocchi F and Rengo F. Twenty-four-hour blood pressure monitoring during treatment with extended-release felodipine versus slow-release nifedipine in elderly patients with mild to moderate hypertension: a randomized, double-blind, cross-over study. Eur J Clin Pharmacol 1997; 53: 95-100.","journal-title":"Eur J Clin Pharmacol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1742-1241.1990.tb10734.x","article-title":"Hypertension in the elderly: a study of a combination of atenolol and nifedipine","volume":"44","author":"Duckett","year":"1990","unstructured":"Duckett GK and Cheadle B. Hypertension in the elderly: a study of a combination of atenolol and nifedipine. Br J Clin Pract 1990; 44: 52-54.","journal-title":"Br J Clin Pract"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Bravo EL, Krakoff LR, Tuck ML and Friedman CP. Antihypertensive effectiveness of nifedipine gastrointestinal therapeutic system in the elderly. The Modern Approach to the Treatment of Hypertension (MATH) Study Group. Am J Hypertens 1990; 3: 326S-332S.","DOI":"10.1093\/ajh\/3.12.326S"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1097\/00004872-199610000-00013","article-title":"Shanghai trial of nifedipine in the elderly (STONE)","volume":"14","author":"Gong","year":"1996","unstructured":"Gong L, Zhang W, Zhu Y, Zhu J, Kong D, Pagé V, Ghadirian P, LeLorier J and Hamet P. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14: 1237-1245.","journal-title":"J Hypertens"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Wang X, Wu J, Liu L, Yang Q, Yu H, Luo W and Yan Z. Clinical effect of combined controlled-release nifedipine tablets-valsartan therapy on elderly patients suffering from type II diabetic nephropathy with hypertension. Biomed Res (India) 2018; 29: 1133-1136.","DOI":"10.4066\/biomedicalresearch.29-17-3620"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Wang XJ, Wu JR, Liu L, Yang Q, Yu HL, Luo WH and Yan ZX. Clinical effect of combined controlled-release nifedipine tablets-valsartan therapy on elderly patients suffering from type II diabetic nephropathy with hypertension. Biomed Res 2018; 29.","DOI":"10.4066\/biomedicalresearch.29-17-3620"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Schneider R, Stolero D, Griffel L, Kobelt R, Brendel E and Iaina A. Pharmacokinetic profile of nifedipine GITS in hypertensive patients with chronic renal impairment. Drugs 1994; 48 Suppl 1: 16-21; discussion 21-22.","DOI":"10.2165\/00003495-199400481-00006"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1291\/hypres.27.181","article-title":"Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial","volume":"27","author":"Yui","year":"2004","unstructured":"Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, Origasa H, Iimura O, Ishii M, Saruta T, Arakawa K, Hosoda S and Kawai C; Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 2004; 27: 181-191.","journal-title":"Hypertens Res"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1291\/hypres.27.449","article-title":"Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) subgroup analysis","volume":"27","author":"Yui","year":"2004","unstructured":"Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, Origasa H, Iimura O, Ishii M, Saruta T, Arakawa K, Hosoda S and Kawai C. Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) subgroup analysis. Hypertens Res 2004; 27: 449-456.","journal-title":"Hypertens Res"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0168-8227(01)00288-1","article-title":"Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics","volume":"54","author":"Baba","year":"2001","unstructured":"Baba S; J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 2001; 54: 191-201.","journal-title":"Diabetes Res Clin Pract"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/01.HYP.0000057420.27692.AD","article-title":"Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT)","volume":"41","author":"Mancia","year":"2003","unstructured":"Mancia G, Brown M, Castaigne A, de Leeuw P, Palmer CR, Rosenthal T, Wagener G and Ruilope LM; INSIGHT. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003; 41: 431-436.","journal-title":"Hypertension"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/S0140-6736(00)02527-7","article-title":"Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)","volume":"356","author":"Brown","year":"2000","unstructured":"Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T and Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-372.","journal-title":"Lancet"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(04)16980-8","article-title":"Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial","volume":"364","author":"Poole-Wilson PA","year":"2004","unstructured":"Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, Just H, Fox KA, Pocock SJ, Clayton TC, Motro M, Parker JD, Bourassa MG, Dart AM, Hildebrandt P, Hjalmarson A, Kragten JA, Molhoek GP, Otterstad JE, Seabra-Gomes R, Soler-Soler J and Weber S; Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364: 849-857.","journal-title":"Lancet"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Webster K, Fishburn S, Maresh M, Findlay SC and Chappell LC; Guideline Committee. Diagnosis and management of hypertension in pregnancy: summary of updated NICE guidance. BMJ 2019; 366: l5119.","DOI":"10.1136\/bmj.l5119"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension Global Hypertension Practice Guidelines","volume":"75","author":"Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, Wainford RD, Williams B and Schutte AE. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 2020; 75: 1334-1357.","journal-title":"Hypertension"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/j.1471-0528.1987.tb02312.x","article-title":"Nifedipine as a second line antihypertensive drug in pregnancy","volume":"94","author":"Constantine","year":"1987","unstructured":"Constantine G, Beevers DG, Reynolds AL and Luesley DM. Nifedipine as a second line antihypertensive drug in pregnancy. Br J Obstet Gynaecol 1987; 94: 1136-1142.","journal-title":"Br J Obstet Gynaecol"},{"key":"ref97","unstructured":"Shen X, Yan J and Ren A. Effect of long-acting nifedipine on blood pressure level, eutocia rate and neonatal health status in patients with pregnancy-induced hypertension. Int J Clin Exp Med 2019; 12: 2605-2611."}],"container-title":["American Journal of Cardiovascular Disease"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcd\/14\/6\/ajcd0160710.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:55:05Z","timestamp":1766022905000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcd\/14\/6\/ajcd0160710.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":98,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/rpmz6407","relation":{},"ISSN":["2160-200X"],"issn-type":[{"value":"2160-200X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}